New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

New York, New York--(Newsfile Corp. - March 27, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Aldeyra Therapeutics, Inc. ("Aldeyra Therapeutics, Inc.") (NASDAQ: ALDX) concerning potential violations of the federal securities laws.Throughout 2024 and 2025, Aldeyra's made forward-looking statements regarding the development and regulatory prospects of reproxalap for the treatment of dry eye disease. Management described the NDA submission and review process in terms ...

ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug Approval Prospects: Levi & Korsinsky Accessibility StatementSkip NavigationAldeyra Therapeutics Stock Falls After FDA Issues Complete Response Letter Rejecting Reproxalap for Dry Eye DiseaseNEW YORK, March 25, 2026 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares dropped approximately 70% after the FDA issued a Complete Res ...

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Aldeyra securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Aldeyra securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Aldeyra [2]. Group 2: Regulatory Issues and Stock Performance - On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [3]. - Following the FDA's announcement, Aldeyra's stock price dropped by $2.99 per share, a decline of 70.7%, closing at $1.24 per share on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX Accessibility StatementSkip Navigation NEW YORK, March 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from allegations that Aldeyra may have issued materially misleading business information to the investing public ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued to the investing public [1] Company Summary - Aldeyra Therapeutics, Inc. is facing scrutiny for potentially misleading information that may have affected its securities [1] - Shareholders who purchased Aldeyra securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes. Let us unpack the key developments and milestones in the biotech space this week. FDA and EU Approvals & Rejections GSK's Lynavoy Wins FDA Approval for Cholestatic Pruritus in PBC GSK plc (GSK), secured for Lynavoy, the first U.S. tre ...

Since Tuesday, the company’s stock has slumped by around 67%.FDA Rejects Aldeyra Reproxalap ApplicationThe company received an FDA Complete Response Letter (CRL) for its New Drug Application for reproxalap, indicating a lack of substantial evidence from controlled studies.The FDA’s letter raised concerns over the efficacy of reproxalap, stating that further trials are not recommended, but suggested exploring specific populations where the drug may be effective.In a statement, Aldeyra’s CEO emphasized the ur ...